Search

Your search keyword '"Scagliotti, Giorgio"' showing total 1,689 results
Start Over Author "Scagliotti, Giorgio"
1,689 results on '"Scagliotti, Giorgio"'

301. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015.

Author

Nicholson, Andrew G., Tsao, Ming S., Beasley, Mary Beth, Borczuk, Alain C., Brambilla, Elisabeth, Cooper, Wendy A., Dacic, Sanja, Jain, Deepali, Kerr, Keith M., Lantuejoul, Sylvie, Noguchi, Masayuki, Papotti, Mauro, Rekhtman, Natasha, Scagliotti, Giorgio, van Schil, Paul, Sholl, Lynette, Yatabe, Yasushi, Yoshida, Akihiko, and Travis, William D.

Published
2022
Full Text
View/download PDF

303. Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report

Author

Dingemans, Anne-Marie C, Hendriks, Lizza E L, Berghmans, Thierry, Levy, Antonin, Hasan, Baktiar, Faivre-Finn, Corinne, Giaj-Levra, Matteo, Giaj-Levra, Niccolò, Girard, Nicolas, Greillier, Laurent, Lantuéjoul, Sylvie, Edwards, John, O’Brien, Mary, Reck, Martin, Smit, Egbert F, Van Schil, Paul, Postmus, Pieter E, Ramella, Sara, Lievens, Yolande, Gaga, Mina, Peled, Nir, Scagliotti, Giorgio V, Senan, Suresh, Paz-Ares, Luiz, Guckenberger, Matthias, McDonald, Fiona, Ekman, Simon, Cufer, Tanja, Gietema, Hester, Infante, Maurizio, et al, University of Zurich, and Dingemans, Anne-Marie C

Subjects
Pulmonary and Respiratory Medicine, Oncology, 2740 Pulmonary and Respiratory Medicine, 610 Medicine & health, 2730 Oncology, 10044 Clinic for Radiation Oncology
Published
2019

304. Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer

Author

Scagliotti, Giorgio Vittorio, Ricardi, Umberto, Crinó, Lucio, Maranzano, Ernesto, Marinis, Filippo De, Morandi, Maria Grazia, Meacci, Luisa, Marangolo, Maurizio, Emiliani, Ermanno, Rosti, Giovanni, Figoli, Franco, Bolzicco, Gianfranco, Masiero, Paolo, Gentile, Alfonso, and Tonato, Maurizio

Published
1996
Full Text
View/download PDF

312. New Approaches to SCLC Therapy: From the Laboratory to the Clinic

Author

Poirier, John T., George, Julie, Owonikoko, Taofeek K., Berns, Anton, Brambilla, Elisabeth, Byers, Lauren A., Carbone, David, Chen, Huanhuan J., Christensen, Camilla L., Dive, Caroline, Farago, Anna, Govindan, Ramaswamy, Hann, Christine, Hellmann, Matthew D., Horn, Leora, Johnson, Jane E., Ju, Young S., Kang, Sumin, Krasnow, Mark, Lee, James, Lee, Se-Hoon, Lehman, Jonathan, Lok, Benjamin, Lovly, Christine, MacPherson, David, McFadden, David, Minna, John, Oser, Matthew, Park, Keunchil, Park, Kwon-Sik, Pommier, Yves, Quaranta, Vito, Ready, Neal, Sage, Julien, Scagliotti, Giorgio, Sos, Martin L., Sutherland, Kate D., Travis, William D., Vakoc, Christopher R., Wait, Sarah J., Wistuba, Ignacio, Wong, Kwok Kin, Zhang, Hua, Daigneault, Jillian, Wiens, Jacinta, Rudin, Charles M., Oliver, Trudy G., Poirier, John T., George, Julie, Owonikoko, Taofeek K., Berns, Anton, Brambilla, Elisabeth, Byers, Lauren A., Carbone, David, Chen, Huanhuan J., Christensen, Camilla L., Dive, Caroline, Farago, Anna, Govindan, Ramaswamy, Hann, Christine, Hellmann, Matthew D., Horn, Leora, Johnson, Jane E., Ju, Young S., Kang, Sumin, Krasnow, Mark, Lee, James, Lee, Se-Hoon, Lehman, Jonathan, Lok, Benjamin, Lovly, Christine, MacPherson, David, McFadden, David, Minna, John, Oser, Matthew, Park, Keunchil, Park, Kwon-Sik, Pommier, Yves, Quaranta, Vito, Ready, Neal, Sage, Julien, Scagliotti, Giorgio, Sos, Martin L., Sutherland, Kate D., Travis, William D., Vakoc, Christopher R., Wait, Sarah J., Wistuba, Ignacio, Wong, Kwok Kin, Zhang, Hua, Daigneault, Jillian, Wiens, Jacinta, Rudin, Charles M., and Oliver, Trudy G.

Abstract

The outcomes of patients with SCLC have not yet been substantially impacted by the revolution in precision oncology, primarily owing to a paucity of genetic alterations in actionable driver oncogenes. Nevertheless, systemic therapies that include immunotherapy are beginning to show promise in the clinic. Although, these results are encouraging, many patients do not respond to, or rapidly recur after, current regimens, necessitating alternative or complementary therapeutic strategies. In this review, we discuss ongoing investigations into the pathobiology of this recalcitrant cancer and the therapeutic vulnerabilities that are exposed by the disease state. Included within this discussion, is a snapshot of the current biomarker and clinical trial landscapes for SCLC. Finally, we identify key knowledge gaps that should be addressed to advance the field in pursuit of reduced SCLC mortality. This review largely summarizes work presented at the Third Biennial International Association for the Study of Lung Cancer SCLC Meeting. (C) 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Published
2020

313. Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.

Author

Garon, Edward B, Garon, Edward B, Scagliotti, Giorgio Vittorio, Gautschi, Oliver, Reck, Martin, Thomas, Michael, Iglesias Docampo, Lara, Kalofonos, Haralabos, Kim, Joo-Hang, Gans, Steven, Brustugun, Odd Terje, Orlov, Sergey V, Cuyun Carter, Gebra, Zimmermann, Annamaria H, Oton, Ana B, Alexandris, Ekaterine, Lee, Pablo, Wolff, Katharina, Stefaniak, Victoria Jennifer, Socinski, Mark A, Pérol, Maurice, Garon, Edward B, Garon, Edward B, Scagliotti, Giorgio Vittorio, Gautschi, Oliver, Reck, Martin, Thomas, Michael, Iglesias Docampo, Lara, Kalofonos, Haralabos, Kim, Joo-Hang, Gans, Steven, Brustugun, Odd Terje, Orlov, Sergey V, Cuyun Carter, Gebra, Zimmermann, Annamaria H, Oton, Ana B, Alexandris, Ekaterine, Lee, Pablo, Wolff, Katharina, Stefaniak, Victoria Jennifer, Socinski, Mark A, and Pérol, Maurice

Abstract

Non-small-cell lung cancer (NSCLC) is a heterogeneous disease. Front-line therapy may affect responses to subsequent treatment regimens, thus influencing second-line therapy decision making. In the randomised phase 3 REVEL study, second-line ramucirumab plus docetaxel (ram+doc) versus docetaxel (doc) improved survival of patients with metastatic NSCLC. We explore efficacy, safety and quality-of-life (QoL) in REVEL based on front-line therapy. Patients were grouped by specific front-line therapy received. Overall survival (OS), progression-free survival (PFS), objective response rate, safety and QoL were assessed descriptively. Kaplan-Meier estimation and Cox proportional hazards modelling were used; frequencies reported in percentages. Baseline characteristics of 1253 patients were generally well balanced between treatment arms within each front-line therapy subgroup. For patients with non-squamous disease (n=912), induction therapies included platinum-based chemotherapy plus a taxane (n=227; 25%) or pemetrexed (n=449; 49%), with (n=172; 19%) or without bevacizumab. For patients with squamous disease (n=328), induction therapies included platinum-based chemotherapy plus gemcitabine (n=176; 54%) or a taxane (n=69; 21%). A highly selected subgroup (n=127; 14%) received pemetrexed continuation maintenance therapy. Ram+doc improved median OS and PFS versus doc across front-line therapy subgroups, as reflected by HRs ranging from 0.78 to 0.91 and 0.66 to 0.92, respectively, similar to results in the overall intention-to-treat cohort (HRs: 0.86 and 0.76, respectively). High-grade treatment-emergent adverse events of special interest (including neutropenia, febrile neutropenia, leucopenia and hypertension) were generally higher in ram+doc-treated patients relative to doc-treated patients regardless of front-line therapy. No clear differences in safety or QoL were seen across front-line therapy subgroups; outcomes were consistent with those reported in the overall intention

Published
2020

314. Recommendations for Implementing Lung Cancer Screening with Low-Dose Computed Tomography in Europe

Author

Veronesi, Giulia, Baldwin, David R, Henschke, Claudia I, Ghislandi, Simone, Iavicoli, Sergio, Oudkerk, Matthijs, De Koning, Harry J, Shemesh, Joseph, Field, John K, Zulueta, Javier J, Horgan, Denis, Fiestas Navarrete, Lucia, Valentino Infante, Maurizio, Novellis, Pierluigi, Murray, Rachael L, Peled, Nir, Rampinelli, Cristiano, Rocco, Gaetano, Rzyman, Witold, Scagliotti, Giorgio Vittorio, Tammemagi, Martin C, Bertolaccini, Luca, Triphuridet, Natthaya, Yip, Rowena, Rossi, Alexia, Senan, Suresh, Ferrante, Giuseppe, Brain, Kate, van der Aalst, Carlijn, Bonomo, Lorenzo, Consonni, Dario, Van Meerbeeck, Jan P, Maisonneuve, Patrick, Novello, Silvia, Devaraj, Anand, Saghir, Zaigham, Pelosi, Giuseppe, Veronesi, Giulia, Baldwin, David R, Henschke, Claudia I, Ghislandi, Simone, Iavicoli, Sergio, Oudkerk, Matthijs, De Koning, Harry J, Shemesh, Joseph, Field, John K, Zulueta, Javier J, Horgan, Denis, Fiestas Navarrete, Lucia, Valentino Infante, Maurizio, Novellis, Pierluigi, Murray, Rachael L, Peled, Nir, Rampinelli, Cristiano, Rocco, Gaetano, Rzyman, Witold, Scagliotti, Giorgio Vittorio, Tammemagi, Martin C, Bertolaccini, Luca, Triphuridet, Natthaya, Yip, Rowena, Rossi, Alexia, Senan, Suresh, Ferrante, Giuseppe, Brain, Kate, van der Aalst, Carlijn, Bonomo, Lorenzo, Consonni, Dario, Van Meerbeeck, Jan P, Maisonneuve, Patrick, Novello, Silvia, Devaraj, Anand, Saghir, Zaigham, and Pelosi, Giuseppe

Abstract

Lung cancer screening (LCS) with low-dose computed tomography (LDCT) was demonstrated in the National Lung Screening Trial (NLST) to reduce mortality from the disease. European mortality data has recently become available from the Nelson randomised controlled trial, which confirmed lung cancer mortality reductions by 26% in men and 39-61% in women. Recent studies in Europe and the USA also showed positive results in screening workers exposed to asbestos. All European experts attending the "Initiative for European Lung Screening (IELS)"-a large international group of physicians and other experts concerned with lung cancer-agreed that LDCT-LCS should be implemented in Europe. However, the economic impact of LDCT-LCS and guidelines for its effective and safe implementation still need to be formulated. To this purpose, the IELS was asked to prepare recommendations to implement LCS and examine outstanding issues. A subgroup carried out a comprehensive literature review on LDCT-LCS and presented findings at a meeting held in Milan in November 2018. The present recommendations reflect that consensus was reached.

Published
2020

320. Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

Author

Giaccone, Giuseppe, Herbst, Roy S., Manegold, Christian, Scagliotti, Giorgio, Rosell, Rafael, Miller, Vincent, Natale, Ronald B., Schiller, Joan H., von Pawel, Joachim, Pluzanska, Anna, Gatzemeier, Ulrich, Grous, John, Ochs, Judith S., Averbuch, Steven D., Wolf, Michael K., Rennie, Pamela, Fandi, Abderrahim, and Johnson, David H.

Published
2004
Full Text
View/download PDF

330. Gemcitabine and Cisplatin as induction chemotherapy for patients with unresectable stage IIIA-bulky N2 and stage IIIB-nonsmall cell lung carcinoma

Author

Cappuzzo, Federico, Selvaggi, Giovanni, Gregorc, Vanesa, Mazzoni, Franscesca, Betti, Maura, Migliorino, Maria Rita, Novello, Silvia, Maestri, Antonio, Marinis, Filippo De, Darwish, Samir, Angelis, Verena De, Nelli, Fabrizio, Bartolini, Stefania, Scagliotti, Giorgio V., Tonato, Mauizio, and Crino, Lucio

Subjects
Lung cancer -- Care and treatment, Cisplatin -- Dosage and administration, Gemcitabine -- Dosage and administration, Health
Published
2003

332. HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma

Author

Selvaggi, Giovanni, Scagliotti, Giorgio V., Torri, Valter, Novello, Silvia, Leonardo, Eugenio, Cappia, Claudio, Ardissone, Francesco, Lausi, Paolo, Borasio, Piero, and Mossetti, Claudio

Subjects
Medical research -- Analysis, Cancer -- Research, Gene expression -- Physiological aspects, Cancer survivors -- Health aspects, Cells -- Genetic aspects, Lung cancer -- Care and treatment, Excision (Surgery) -- Analysis, Health
Published
2002

340. The accuracy of clinical staging of stage I-IIIa non-small cell lung cancer : an analysis based on individual participant data

Author

Navani, Neal, Fisher, David J., Tierney, Jayne F., Stephens, Richard J., Burdett, Sarah, Rydzewska, Larysa H. M., Auperin, Anne, Le Chevalier, Thierry, Le Pechoux, Cécile, Pignon, Jean-Pierre, Arriagada, Rodrigo, Johnson, David H., van Meerbeeck, Jan, Parmar, Mahesh K. B., Stewart, Lesley A., Bunn, Paul A., Dautzenberg, Bertrand, Gilligan, David, Groen, Harry, Knuuttila, Aija, Vallieres, Eric, Rosell, Rafael, Roth, Jack, Scagliotti, Giorgio, Tsuboi, Masahiro, Waller, David, Westeel, Virginie, Yi-Long, Wu, Yang, Xue-Ning, and NSCLC Meta Anal Collaborative Grp

Subjects
meta-analysis, Pulmonary and Respiratory Medicine, staging, Human medicine, Critical Care and Intensive Care Medicine, Cardiology and Cardiovascular Medicine, non-small cell lung cancer
Abstract

BACKGROUND: Clinical staging of non-small cell lung cancer (NSCLC) helps determine the prognosis and treatment of patients; few data exist on the accuracy of clinical staging and the impact on treatment and survival of patients. We assessed whether participant or trial characteristics were associated with clinical staging accuracy as well as impact on survival. METHODS: We used individual participant data from randomized controlled trials (RCTs), supplied for a meta-analysis of preoperative chemotherapy (+/- radiotherapy) vs surgery alone (+/- radiotherapy) in NSCLC. We assessed agreement between clinical TNM (cTNM) stage at randomization and pathologic TNM (pTNM) stage, for participants in the control group. RESULT: Results are based on 698 patients who received surgery alone (+/- radiotherapy) with data for cTNM and pTNM stage. Forty-six percent of cases were cTNM stage I, 23% were cTNM stage II, and 31% were cTNM stage IIIa. cTNM stage disagreed with pTNM stage in 48% of cases, with 34% clinically understaged and 14% clinically overstaged. Agreement was not associated with age (P = .12), sex (P = .62), histology (P = .82), staging method (P = .32), or year of randomization (P = .98). Poorer survival in understaged patients was explained by the underlying pTNM stage. Clinical staging failed to detect T4 disease in 10% of cases and misclassified nodal disease in 38%. CONCLUSION: This study demonstrates suboptimal agreement between clinical and pathologic staging. Discrepancies between clinical and pathologic T and N staging could have led to different treatment decisions in 10% and 38% of cases, respectively. There is therefore a need for further research into improving staging accuracy for patients with stage I-IIIa NSCLC.

Published
2019

342. Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018

Author

Reale, Maria Lucia, primary, De Luca, Emmanuele, additional, Lombardi, Pasquale, additional, Marandino, Laura, additional, Zichi, Clizia, additional, Pignataro, Daniele, additional, Ghisoni, Eleonora, additional, Di Stefano, Rosario F., additional, Mariniello, Annapaola, additional, Trevisi, Elena, additional, Leone, Gianmarco, additional, Muratori, Leonardo, additional, La Salvia, Anna, additional, Sonetto, Cristina, additional, Bironzo, Paolo, additional, Aglietta, Massimo, additional, Novello, Silvia, additional, Scagliotti, Giorgio V., additional, Perrone, Francesco, additional, and Di Maio, Massimo, additional

Published
2020
Full Text
View/download PDF

343. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Author

Petrylak, Daniel P, primary, de Wit, Ronald, additional, Chi, Kim N, additional, Drakaki, Alexandra, additional, Sternberg, Cora N, additional, Nishiyama, Hiroyuki, additional, Castellano, Daniel, additional, Hussain, Syed A, additional, Fléchon, Aude, additional, Bamias, Aristotelis, additional, Yu, Evan Y, additional, van der Heijden, Michiel S, additional, Matsubara, Nobuaki, additional, Alekseev, Boris, additional, Necchi, Andrea, additional, Géczi, Lajos, additional, Ou, Yen-Chuan, additional, Coskun, Hasan Senol, additional, Su, Wen-Pin, additional, Bedke, Jens, additional, Gakis, Georgios, additional, Percent, Ivor J, additional, Lee, Jae-Lyun, additional, Tucci, Marcello, additional, Semenov, Andrey, additional, Laestadius, Fredrik, additional, Peer, Avivit, additional, Tortora, Giampaolo, additional, Safina, Sufia, additional, Garcia del Muro, Xavier, additional, Rodriguez-Vida, Alejo, additional, Cicin, Irfan, additional, Harputluoglu, Hakan, additional, Tagawa, Scott T, additional, Vaishampayan, Ulka, additional, Aragon-Ching, Jeanny B, additional, Hamid, Oday, additional, Liepa, Astra M, additional, Wijayawardana, Sameera, additional, Russo, Francesca, additional, Walgren, Richard A, additional, Zimmermann, Annamaria H, additional, Hozak, Rebecca R, additional, Bell-McGuinn, Katherine M, additional, Powles, Thomas, additional, Wong, Suet-Lai Shirley, additional, Tan, Thean Hsiang, additional, Hovey, Elizabeth Jane, additional, Clay, Timothy Dudley, additional, Wan Ng, Siobhan Su, additional, Rutten, Annemie, additional, Machiels, Jean-Pascal, additional, Dumez, Herlinde, additional, Cheng, Susanna Yee-Shan, additional, Ferrario, Cristiano, additional, Sengeloev, Lisa, additional, Jensen, Niels Viggo, additional, Thibault, Constance, additional, Laguerre, Brigitte, additional, Joly, Florence, additional, Culine, Stéphane, additional, Becht, Catherine, additional, Niegisch, Günter, additional, Stöckle, Michael, additional, Grimm, Marc-Oliver, additional, Schwentner, Christina A, additional, Schultze-Seemann, Wolfgang, additional, Kalofonos, Haralambos, additional, Mavroudis, Dimitrios, additional, Papandreou, Christos, additional, Karavasilis, Vasilis, additional, Révész, Janos, additional, Rosenbaum, Eli, additional, Leibowitz-Amit, Raya, additional, Kejzman, Daniel, additional, Sarid, David, additional, Scagliotti, Giorgio Vittorio, additional, Bracarda, Sergio, additional, Massari, Francesco, additional, Osawa, Takahiro, additional, Miyajima, Naoto, additional, Shinohara, Nobuo, additional, Fukuta, Fumimasa, additional, Ohyama, Chikara, additional, Obara, Wataru, additional, Yamashita, Shinichi, additional, Tomita, Yoshihiko, additional, Kawai, Koji, additional, Fukasawa, Satoshi, additional, Oyama, Masafumi, additional, Yonese, Junji, additional, Nagata, Masayoshi, additional, Uemura, Motohide, additional, Nishimura, Kazuo, additional, Kawakita, Mutsushi, additional, Tsunemori, Hiroyuki, additional, Hashine, Katsuyoshi, additional, Inokuchi, Junichi, additional, Yokomizo, Akira, additional, Nagamori, Satoshi, additional, Lee, Hyo Jin, additional, Park, Se Hoon, additional, Rha, Sun Young, additional, Kim, Yu Jung, additional, Lee, Yun-Gyoo, additional, Vazquez Cortés, Leticia, additional, Lorena Urzua Flores, Claudia, additional, Blaisse, Reinoud J.B., additional, Erdkamp, Fransiscus L.G., additional, Aarts, Maureen J.B., additional, Wojcik-Tomaszewska, Joanna, additional, Tomczak, Piotr, additional, Sikora-Kupis, Bozena, additional, Schenker, Michael, additional, Herzal, Alina Amalia, additional, Udrea, Anghel Adrian, additional, Karlov, Petr, additional, Fomkin, Roman, additional, Gajate Borau, Pablo, additional, Grande, Enrique, additional, Delgado Mignorance, Juan Ignacio, additional, Su, Yu-Li, additional, Li, Jian-Ri, additional, Lin, Chien-Liang, additional, Lin, Chia-Chi, additional, Yeh, Su-Peng, additional, Erman, Mustafa, additional, Urun, Yuksel, additional, Golovko, Yuriy, additional, Bondarenko, Igor, additional, Sinielnikov, Ivan, additional, Crabb, Simon J., additional, Syndikus, Isabel, additional, Huddart, Robert, additional, Sundar, Santhanam, additional, Chowdhury, Simon, additional, Sarwar, Naveed, additional, Flaig, Thomas W., additional, Pan, Chong Xian, additional, Schwarz, James K., additional, Cultrera, Jennifer Lyn, additional, Acs, Peter Istvan, additional, Hainsworth, John D., additional, Herms, Benjamin T., additional, Lawler, William Eyre, additional, and Lowe, Thomas Eugene, additional

Published
2020
Full Text
View/download PDF

344. A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients

Author

Scagliotti, Giorgio, primary, Moro-Sibilot, Denis, additional, Kollmeier, Jens, additional, Favaretto, Adolfo, additional, Cho, Eun Kyung, additional, Grosch, Heidrun, additional, Kimmich, Martin, additional, Girard, Nicolas, additional, Tsai, Chun-Ming, additional, Hsia, Te-Chun, additional, Brighenti, Matteo, additional, Schumann, Christian, additional, Wang, Xuejing Aimee, additional, Wijayawardana, Sameera R., additional, Gruver, Aaron M., additional, Wallin, Johan, additional, Mansouri, Kambiz, additional, Wacheck, Volker, additional, and Chang, Gee-Chen, additional

Published
2020
Full Text
View/download PDF

345. Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy

Author

Garon, Edward B., primary, Scagliotti, Giorgio Vittorio, additional, Gautschi, Oliver, additional, Reck, Martin, additional, Thomas, Michael, additional, Iglesias Docampo, Lara, additional, Kalofonos, Haralabos, additional, Kim, Joo-Hang, additional, Gans, Steven, additional, Te Brustugun, Oddrje, additional, Orlov, Sergey V., additional, Cuyun Carter, Gebra, additional, Zimmermann, Annamaria H., additional, Oton, Ana B., additional, Alexandris, Ekaterine, additional, Lee, Pablo, additional, Wolff, Katharina, additional, Stefaniak, Victoria Jennifer, additional, Socinski, Mark A., additional, and Pérol, Maurice, additional

Published
2020
Full Text
View/download PDF

347. Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions

Author

Tucci,Marcello, Zichi,Clizia, Buttigliero,Consuelo, Vignani,Francesca, Scagliotti,Giorgio V., and Di Maio,Massimo

Subjects
OncoTargets and Therapy
Abstract

Marcello Tucci,1,* Clizia Zichi,1,* Consuelo Buttigliero,1 Francesca Vignani,2 Giorgio V Scagliotti,1 Massimo Di Maio2 1Division of Medical Oncology, Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, 10043 Orbassano, Turin, Italy; 2Division of Medical Oncology, Ordine Mauriziano Hospital, Torino, Italy *These authors contributed equally to this work Abstract: The new-generation hormonal agent enzalutamide has been approved for the treatment of metastatic castration-resistant prostate cancer (CRPC), in both post- and predocetaxel setting, due to the significant improvement in overall survival. More recently, enzalutamide also showed impressive results in the treatment of men with nonmetastatic CRPC. Unfortunately, not all patients with CRPC are responsive to enzalutamide, and even in responders, benefits are limited by the development of drug resistance. Adaptive resistance of metastatic prostate cancer to enzalutamide treatment can be due to the activation of both androgen receptor (AR)-dependent pathways (expression of constitutively active AR splice variants, AR point mutations, gene amplification and overexpression) and mechanisms independent of AR signaling pathway (altered steroidogenesis, upregulation of the glucocorticoid receptor, epithelial–mesenchymal transition, neuroendocrine transformation, autophagy and activation of the immune system). In this review, we focus on resistance mechanisms to enzalutamide, exploring how we could overcome them through novel therapeutic options. Keywords: prostate cancer, enzalutamide, hormonal treatment, mechanisms of resistance, castration-resistant prostate cancer, androgen receptor

Published
2018

348. Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report

Author

Dingemans, Anne-Marie C., primary, Hendriks, Lizza E.L., additional, Berghmans, Thierry, additional, Levy, Antonin, additional, Hasan, Baktiar, additional, Faivre-Finn, Corinne, additional, Giaj-Levra, Matteo, additional, Giaj-Levra, Niccolò, additional, Girard, Nicolas, additional, Greillier, Laurent, additional, Lantuéjoul, Sylvie, additional, Edwards, John, additional, O’Brien, Mary, additional, Reck, Martin, additional, Smit, Egbert F., additional, Van Schil, Paul, additional, Postmus, Pieter E., additional, Ramella, Sara, additional, Lievens, Yolande, additional, Gaga, Mina, additional, Peled, Nir, additional, Scagliotti, Giorgio V., additional, Senan, Suresh, additional, Paz-Ares, Luiz, additional, Guckenberger, Matthias, additional, McDonald, Fiona, additional, Ekman, Simon, additional, Cufer, Tanja, additional, Gietema, Hester, additional, Infante, Maurizio, additional, Dziadziuszko, Rafal, additional, Peters, Solange, additional, Porta, Ramon Rami, additional, Vansteenkiste, Johan, additional, Dooms, Christophe, additional, de Ruysscher, Dirk, additional, Besse, Benjamin, additional, and Novello, Silvia, additional

Published
2019
Full Text
View/download PDF

350. Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018

Author

Marandino, Laura, primary, De Luca, Emmanuele, additional, Zichi, Clizia, additional, Lombardi, Pasquale, additional, Reale, Maria Lucia, additional, Pignataro, Daniele, additional, Di Stefano, Rosario F., additional, Ghisoni, Eleonora, additional, Mariniello, Annapaola, additional, Trevisi, Elena, additional, Leone, Gianmarco, additional, Muratori, Leonardo, additional, La Salvia, Anna, additional, Sonetto, Cristina, additional, Buttigliero, Consuelo, additional, Tucci, Marcello, additional, Aglietta, Massimo, additional, Novello, Silvia, additional, Scagliotti, Giorgio V., additional, Perrone, Francesco, additional, and Di Maio, Massimo, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results